{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:01:09Z","timestamp":1785333669332,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100022815","name":"Beijing Tongren Hospital","doi-asserted-by":"publisher","award":["No. 2021-YJJ-ZZL-049"],"award-info":[{"award-number":["No. 2021-YJJ-ZZL-049"]}],"id":[{"id":"10.13039\/100022815","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-025-02488-1","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T03:10:37Z","timestamp":1747019437000},"page":"1811-1820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-3582","authenticated-orcid":false,"given":"Xiaoya","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2488_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221\u20131231","journal-title":"N Engl J Med"},{"issue":"9","key":"2488_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic rev epidemiology of non-alcoholic fatty liver disease in Asia and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851\u2013861","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2488_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12664-020-01018-x","volume":"39","author":"SW Wong","year":"2020","unstructured":"Wong SW, Chan WK (2020) Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol 39(1):1\u20138","journal-title":"Indian J Gastroenterol"},{"issue":"6","key":"2488_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"EASD EASL","year":"2016","unstructured":"EASL EASD, EASO (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388\u20131402","journal-title":"J Hepatol"},{"issue":"4","key":"2488_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, Avila LD et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793\u2013801","journal-title":"J Hepatol"},{"key":"2488_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS (2019) Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 92:82\u201397","journal-title":"Metabolism"},{"key":"2488_CR7","doi-asserted-by":"publisher","first-page":"154203","DOI":"10.1016\/j.metabol.2020.154203","volume":"111S","author":"SA Polyzos","year":"2020","unstructured":"Polyzos SA, Kang ES, Boutari C et al (2020) Current and emerging Pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 111S:154203","journal-title":"Metabolism"},{"key":"2488_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.diabres.2018.05.017","volume":"142","author":"N Kurinami","year":"2018","unstructured":"Kurinami N, Sugiyama S, Yoshida A et al (2018) Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract 142:254\u2013263","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2488_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K et al (2019) Evaluation of the effects of Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 21(2):285\u2013292","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2488_CR10","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.3390\/ijms22126332","volume":"22","author":"N Perakakis","year":"2021","unstructured":"Perakakis N, Chrysafi P, Feigh M et al (2021) Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH. Int J Mol Sci 22(12):6332","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2488_CR11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1172\/JCI21025","volume":"113","author":"M Watanabe","year":"2004","unstructured":"Watanabe M, Houten SM, Wang L et al (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113(10):1408\u20131418","journal-title":"J Clin Invest"},{"issue":"3","key":"2488_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","volume":"89","author":"MS Brown","year":"1997","unstructured":"Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89(3):331\u2013340","journal-title":"Cell"},{"issue":"5","key":"2488_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1172\/JCI119248","volume":"99","author":"H Shimano","year":"1997","unstructured":"Shimano H, Horton JD, Shimomura I et al (1997) Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of Transgenic mice and in cultured cells. J Clin Invest 99(5):846\u2013854","journal-title":"J Clin Invest"},{"key":"2488_CR14","doi-asserted-by":"crossref","unstructured":"Hernandez-Rodas MC, Valenzuela R, Echeverria F et al (2017) Supplementation with docosahexaenoic acid and extra Virgin Olive oil prevents liver steatosis induced by a high-fat diet in mice through PPAR-\u03b1 and Nrf2 upregulation with concomitant SREBP-1c and NF-\u03baB downregulation. Mol Nutr Food Res 61(12)","DOI":"10.1002\/mnfr.201700479"},{"key":"2488_CR15","doi-asserted-by":"publisher","first-page":"154324","DOI":"10.1016\/j.metabol.2020.154324","volume":"111","author":"R Wei","year":"2020","unstructured":"Wei R, Cui XN, Feng J et al (2020) Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice. Metabolism 111:154324","journal-title":"Metabolism"},{"issue":"3","key":"2488_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1039\/D0FO02387F","volume":"12","author":"XY Sun","year":"2021","unstructured":"Sun XY, Cao ZQ, Ma YY et al (2021) Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis via activating the PI3K\/Akt pathway and suppressing the FoxO1 pathway in type 2 diabetes. Food Funct 12(3):1207\u20131218","journal-title":"Food Funct"},{"issue":"2","key":"2488_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10557-018-6778-x","volume":"32","author":"Y Birnbaum","year":"2018","unstructured":"Birnbaum Y, Bajaj M, Yang HC et al (2018) Combined SGLT2 and DPP4 Inhibition reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes. Cardiovasc Drugs Ther 32(2):135\u2013145","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"2488_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Natta MV et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313\u20131321","journal-title":"Hepatology"},{"issue":"1","key":"2488_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat K, Kleiner DE, Niemeier HM et al (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51(1):121\u2013129","journal-title":"Hepatology"},{"issue":"18","key":"2488_CR20","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P (2018) Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty acid liver disease. Cell Mol Life Sci 75(18):3313\u20133327","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"2488_CR21","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/oby.22559","volume":"27","author":"RJ Perry","year":"2019","unstructured":"Perry RJ (2019) Novel strategies to treat hepatic steatosis and steatohepatitis. Obesity 27(9):1385\u20131387","journal-title":"Obesity"},{"key":"2488_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fendo.2017.00006","volume":"8","author":"A Chaudhury","year":"2017","unstructured":"Chaudhury A, Duvoor C, Reddy Dendi VS et al (2017) Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol 8:6","journal-title":"Front Endocrinol"},{"issue":"22","key":"2488_CR23","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"4","key":"2488_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"issue":"4","key":"2488_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334","journal-title":"N Engl J Med"},{"issue":"1","key":"2488_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13300-017-0355-3","volume":"9","author":"PCH Lee","year":"2018","unstructured":"Lee PCH, Gu Y, Yeung MY et al (2018) Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among Chinese subjects with diabetes in part through glycemic improvement: a single-center, retrospective, observational study. Diabetes Ther 9(1):285\u2013295","journal-title":"Diabetes Ther"},{"issue":"9896","key":"2488_CR27","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon K et al (2013) Efficacy and safety of Canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with Metformin (CANTATASU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941\u2013950","journal-title":"Lancet"},{"issue":"4","key":"2488_CR28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdi.12980","volume":"10","author":"M Inoue","year":"2019","unstructured":"Inoue M, Hayashi A, Taguchi T et al (2019) Effects of Canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig 10(4):1004\u20131011","journal-title":"J Diabetes Investig"},{"key":"2488_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu L, Nagata N, Nagashimada M et al (2017) SGLT2 Inhibition by empagliflozin promotes fat utilization and Browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 20:137\u2013149","journal-title":"EBioMedicine"},{"issue":"5","key":"2488_CR30","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s10620-015-4025-x","volume":"61","author":"MJ Czaja","year":"2016","unstructured":"Czaja MJ (2016) Function of autophagy in nonalcoholic fatty liver disease. Dig Dis Sci 61(5):1304\u20131313","journal-title":"Dig Dis Sci"},{"key":"2488_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MOL.0b013e3283541cfc","volume":"23","author":"AS Wierzbicki","year":"2012","unstructured":"Wierzbicki AS, Oben J (2012) Nonalcoholic fatty acid liver disease and lipids. Curr Opin Lipidol 23:345\u2013352","journal-title":"Curr Opin Lipidol"},{"key":"2488_CR32","first-page":"27","volume":"98","author":"K Omori","year":"2019","unstructured":"Omori K, Nakamura A, Miyoshi et al (2019) Effects of Dapagliflozin and\/or insulin glargine on beta cell mass and hepatic steatosis in Db\/db mice. Comp Study 98:27\u201336","journal-title":"Comp Study"},{"issue":"10","key":"2488_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.tem.2008.08.005","volume":"19","author":"H Tilg","year":"2008","unstructured":"Tilg H, Moschen AR (2008) Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19(10):371\u2013379","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2488_CR34","doi-asserted-by":"publisher","first-page":"e000783","DOI":"10.1136\/bmjdrc-2019-000783","volume":"7","author":"L Xu","year":"2019","unstructured":"Xu L, Nagata N, Chen G et al (2019) Empagliflozin reverses obesity and insulin resistance through fat Browning and alternative macrophage activation in mice fed a high-fat diet. BMJ Open Diabetes Res Care 7(1):e000783","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"2488_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s00125-022-05851-x","volume":"66","author":"B Radlinger","year":"2023","unstructured":"Radlinger B, Ress C, Folie S et al (2023) Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis. Diabetologia 66(4):754\u2013767","journal-title":"Diabetologia"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02488-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:41:01Z","timestamp":1761907261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02488-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["2488"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02488-1","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal studies were approved by the Animal Care and Use Committee of Beijing Tongren Hospital Affiliated to Capital Medical University (No. TRLAWEC2024-20).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}